Research programme: antibacterial therapeutics - Kane Biotech

Drug Profile

Research programme: antibacterial therapeutics - Kane Biotech

Alternative Names: Biofilm inhibitors - Kane Therapeutics; Dispersin B-based antibiofilm therapeutics - Kane Biotech; Dispersin B-based wound care therapeutics - Kane Biotech; Dispersin B/Gentamicin; DispersinB Topical wound gel; DispersinB-Gentamicin wound gel spray; Gentamicin/dispersin B

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Developer Kane Biotech
  • Class Aminoglycosides; Anti-inflammatories; Antibacterials; Proteins; Small molecules
  • Mechanism of Action Glycoside hydrolase stimulants; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections
  • Research Skin disorders

Most Recent Events

  • 31 Jul 2018 Kane Biotech signs CRADA extension with the US Army Institute of Surgical Research (USAISR) for the development of dispersin B-based products for Bacterial infections
  • 31 May 2018 Early research in Skin disorders in Canada (unspecified route) prior to May 2018
  • 17 May 2018 Kane Biotech announces intention to launch DispersinB® based products in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top